Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins
- PMID: 1540978
- PMCID: PMC11038811
- DOI: 10.1007/BF01741553
Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins
Abstract
Drug resistance of tumor cells has led to the development of other therapeutic modalities including biological response modifiers, lymphokine-activated killer cells (LAK), and cytokines alone and in combination. The premise of these alternative modalities is that drug resistance can be overcome by other cytotoxic agents or cytotoxic effector cells. However, the relationship between tumor cell sensitivity to these different agents and the cytotoxicity caused by drugs is not known or well understood. Thus, understanding the relationship between these different systems of tumor cell cytotoxicity is essential for optimal therapeutic intervention. To this end, we compared the tumor cell cytotoxicity mediated by recombinant tumor necrosis factor (rTNF), cytotoxic effector cells (natural killer cells, monocytes, LAK cells), chemotherapeutic drugs, and microbial toxins. Human tumor cell lines sensitive and resistant to rTNF or drugs were used to evaluate the effectiveness of the other cytotoxic modalities. Sensitivity was considered as tumor cell cytotoxicity above 15% while resistance refers to that below 10%. Cell lines tested consisted of several histological types such as brain, lung, colon and ovarian tumors. In our experiments, cell lines made resistant to rTNF by coculture were also relatively resistant to unactivated monocytes and their supernatants. These lines were sensitive to all other methods tested including activated monocytes, natural killer and LAK cells, drugs, and toxins. The tumor lines naturally resistant to rTNF were found to have various degrees of sensitivity and resistance to these other systems. Upon the analysis of our data, a pattern emerged that suggested a hierarchy of sensitivity and resistance of the tumor cells to the cytotoxic mechanisms explored. From a majority of cell lines resistant to rTNF to a minority of lines resistant to LAK, we found an interesting gradation of sensitivity and/or resistance to the other cytotoxic modalities employed. The hypothesis of an underlying common mechanism of action within these systems is discussed.
Similar articles
-
Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.Immunol Lett. 1991 Mar;27(3):191-7. doi: 10.1016/0165-2478(91)90150-9. Immunol Lett. 1991. PMID: 2060970
-
Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.Cancer Res. 1990 Sep 15;50(18):5931-6. Cancer Res. 1990. PMID: 1975512
-
Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents.Cell Immunol. 1989 Apr 15;120(1):250-8. doi: 10.1016/0008-8749(89)90192-5. Cell Immunol. 1989. PMID: 2784721
-
Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.Leuk Res. 1992;16(3):287-98. doi: 10.1016/0145-2126(92)90067-h. Leuk Res. 1992. PMID: 1560676
-
Regulation of natural killer function by nonlymphoid cells.Nat Immun. 1993 Jul-Oct;12(4-5):235-49. Nat Immun. 1993. PMID: 8257829 Review.
Cited by
-
Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.Cancer Immunol Immunother. 1993 Oct;37(5):337-42. doi: 10.1007/BF01518457. Cancer Immunol Immunother. 1993. PMID: 8402737 Free PMC article.
References
-
- Barton RL, Briggs SL, Koppel GA. Monoclonal antibody drug targeting. Drugs News and Perspectives. 1991;4:73–88.
-
- Bonavida B, Wright SC. Multistage model of NK cell mediated cytotoxicity involving NKCF as soluable cytotoxic mediators. Adv Can Res. 1987;49:169–187. - PubMed
-
- Bonavida B, Tsuchitani T, Safrit J, Zighelboim J. Mechanism of target cell lysis by cytotoxic cells, factors, and drugs. In: Tapiero H, Robert J, Lampidis TJ, editors. Anti cancer drugs. Colloque INSERM. London: Libbey Eurotext; 1989. pp. 113–128.
-
- Brunda MJ, Davatelis V. Augmentation of NK cell activity by recombinant IL-2 and recombinant IFNs. In: Herberman R, editor. Mechanisms of cytotoxicity by NK cells. New York: Academic Press; 1985. pp. 397–407.
-
- Capel ID, Leach D, Dorrel HM. Vitamin E retards the lipoperoxidation resulting from anticancer drug administration. Anticancer Res. 1983;3:59–62. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources